TRI is pleased to announce its new Clinical and Translational Science Pilot Program (CTSP2) with two grant opportunities for 2024:

• Collaborative Clinical and Translational Science Pilot Program. This funding will support team approaches in translational science among mid-level and senior faculty in durable collaborations and generate data to advance to extramural funding. Budgets up to $50,000 for a one-year period will be considered.
• Early Career Clinical and Translational Science Pilot Program. This funding will support projects by early-career faculty that generate critical data to improve competitiveness for future extramural funding.  Budgets up to $25,000 for a one-year period will be considered.

The CTSP2 seeks proposals for projects that include one or more principles of translational science as defined here by the National Center for the Advancement of Translational Sciences (NCATS).

The Letter of Application deadline has been extended to Monday, May 13. All projects funded under these pilot programs must be completed by June 30, 2025. 

Please attend a Q&A session to learn more about these funding opportunities on Tuesday, April 23 at 2 p.m., or Tuesday, May 7 at 11 a.m.  Register here.

Learn more at the TRI website.

View the Funding Opportunity Announcement (FOA) for mid-level and senior faculty.

View the FOA for early career investigators.

Contact: Hailey Rogers, HRogers@uams.edu.

Principal Investigator: Nishank Jain, M.D., associate professor, UAMS College of Medicine, Department of Internal Medicine, Division of Nephrology; TRI KL2 Mentored Research Career Development Program Scholar

Summary: An investigator-initiated study analyzing blood samples of adults with chronic kidney disease (CKD), adults with kidney transplants, and healthy adults to understand the interactions between platelets and leukocytes as possible drivers of inflammation in CKD.

Significance: CKD patients have abnormal inflammation associated with higher risks for heart attack and stroke. Having established that platelets are a primary cause, Jain hopes to identify the abnormal inflammatory pathways in CKD patients so that therapeutics may be found to inhibit platelets and reduce patients’ inflammatory burden.

TRI Services: ARresearch participant registry

Funding Agency: NIHNational Center for Advancing Translational Sciences

Learn more about the participant registry at TRI.uams.edu and ARresearch.org.

In this issue of The TRIbune, we highlight the latest clinical trial success led by Stacie Jones, M.D., and Amy Scurlock, M.D., UAMS researchers at Arkansas Children’s Hospital and Research Institute.

Their decades-long research careers have included consequential collaborations in national clinical trials of new treatments for food allergies. Their work shows how clinical trials can benefit Arkansans, and Jones is helping bring additional clinical trials to researchers at Arkansas Children’s Research Institute in her role as a TRI liaison to the national CTSA Trial Innovation Network.

This issue of The TRIbune also includes a story and link to a video presentation to help researchers understand the difference between translational research and translational science.

TRI Director Laura James, M.D., is also featured for her work leading a national project to help improve clinical trials, which was published in February in the Journal of Clinical and Translational Science.

Our TRI Study of the Month features Nishank Jain, M.D., whose kidney-related research has been aided by the ARresearch registry of potential research volunteers. 

Read The TRIbune.

The terms translational research and translational science have been used interchangeably for more than a decade, but that’s changing across Clinical and Translational Science Awards (CTSA)-funded institutions, including TRI.

Driving the transformation is the NIH National Center for Advancing Translational Sciences (NCATS), which funds the CTSA program. Beginning in July of 2024, TRI supported awardees and trainees will need to explain how their research addresses both translational research and translational science. Translational research addresses overcoming a barrier to propel a specific research project forward to develop new treatments or treatment approaches for patients. Translational science takes a step back from the specific research project to ask broader questions such as a) how can the research approach support future research projects or be used by other researchers? or b) how can barriers to research be mitigated to support the broader research community and to support future research? Barriers may be scientific or administrative.  

Translational science is the “science of translational research,” said TRI Director Laura James, M.D. The ultimate goal of translational science is to identify “best practice approaches” for translational research that have broad application for numerous researchers and research disciplines.  One recent example of translational science is the wide-scale use of electronic health records to better understand the impact of COVID-19 on specific patient groups. NCATS created the NC3 data enclave – a national data infrastructure based on electronic health records from over 75 institutions – to better understand COVID-19.

A recorded video presentation on the topic is now available. The video is a condensed version of a recent TRI seminar led by J. Rob Singleton, M.D., director of the University of Utah’s Clinical Research Unit at the Clinical and Translational Science Institute.

View the presentation here.

In this issue of The TRIbune, we feature a notable achievement led by Pearl McElfish, Ph.D., MBA, and Krista Langston, MBA, that is improving the pay of community health workers. They successfully established a career ladder program in 2023 that raises salaries with additional training, certifications, as well as an opportunity to obtain college credit. Community health workers serve a number of roles, and as trusted members of the communities they serve, they are increasingly important to TRI’s research efforts.

We also highlight our Community Engagement team and its important role providing consultations on community-based research.

This issue also features the NIH-supported biomedical informatics study led by Tremaine Williams, Ed.D., a 2023 graduate of the TRI KL2 Mentored Research Career Development Scholar Award Program.

Read The TRIbune.

Megha Sharma, M.D. M.S., found the perfect way to increase her clinical and translational science skills and help advance her research career. She received a scholarship that provided protected time so she could earn a UAMS Master of Science in Clinical and Translational Sciences (MS-CTS) degree.

Sharma, an assistant professor in the College of Medicine Department of Pediatrics, Division of Neonatology, earned the degree in 2023. She was able to leverage her expanded skillset to secure a prestigious KL2 Mentored Research Career Development Scholar Award and the Marion B. Lyon Revocable Trust New Scientist Development Award offered by the Arkansas Children’s Research Institute.

“I had a fantastic experience in the master’s program,” she said. “I learned to apply what I learned through advanced biostatistics, bioinformatics, epidemiology, and clinical trial design to write a competitive grant application. With guidance from experienced mentors, this experience also helped me develop the art and science of asking the right research question and enriched my understanding of rigorous scientific methods.”  

The MS-CTS program is offered by the UAMS Graduate School. Scholars’ protected time is secured by the Translational Research Institute (TRI) with support from the individual scholar’s department.

The MS-CTS program serves as a feeder program to TRI’s KL2 program as well as other early-career development K awards. (TRI’s KL2 program is transitioning to the K12 program this year, offering the same benefits to its scholars.)

Jenny Rumpel, M.D., another MS-CTS scholarship recipient and graduate of the program, received a KL2 in 2022 and has applied for an NIH K23 Mentored Patient-Oriented Research Career Development Award.

The master’s program, she said, helped her develop skills that will be invaluable to her career.

“It broadened my understanding of the possibilities in clinical research design through collaboration with researchers from other departments,” said Rumpel, an assistant professor in the Department of Pediatrics. “I loved that there was strong focus on grant writing skills right as I walked into the program.”

She said the program has also been invaluable for getting to know other TRI-supported researchers and finding prospective research mentors.

“I have met some great new friends,” Rumpel said.

Learn more here about the MS-CTS Scholarship Program and view the 2024 application form.

TRI is excited to announce that registration is now open for a grant-writing workshop March 21 and 22 by the AtKisson Training Group (ATG). 

Don’t miss out on this exclusive opportunity to elevate your grant-writing skills at this free workshop sponsored by TRI and the UAMS Office of Community Health & Research.

Workshop Focus: Structuring NIH Proposals

Time: 9 a.m. to noon (Thursday and Friday)

Location: Virtual

Lead Presenter: M.S. (Peg) AtKisson, Ph.D., an acclaimed public speaker, trainer and former neuroscientist at Tufts University.

What to Expect: Hands-on activities focusing on the Specific Aims and Research Strategy sections of an NIH proposal. Dive deep into the mechanics of effective proposal construction and writing. Engage in practical exercises using both sample documents and sections related to your own proposals. This workshop promises vital insights and strategies to improve your grant application success.

Please register here. 

“Dr. AtKisson and her team provide engaging, hands-on seminars filled with practical examples and exercises that will immediately impact the quality of your grant writing and funding success. I highly recommend the ATG Training Group to take your grant writing to the next level.” – Mario Schootman, Ph.D., co-director, TRI Translational Workforce Development

Contact: Adam Kleinerman, akleinerman@uams.edu

A University of Arkansas for Medical Sciences (UAMS) research team led by Tremaine Williams, Ed.D., has received a National Institutes of Health (NIH) grant to better understand how nurses influence outcomes of heart failure patients.

About 6.2 million people in the United States have heart failure. The two-year, $406,897 R21 grant from the NIH National Institute of Nursing Research (NINR) will focus on African American heart failure patients, whose hospitalization rates are nearly 2.5 times that of white heart failure patients nationally.

The collaboration with UAMS nurses and nursing leadership will enable Williams to document how nurses use individualized patient risk factors (risk stratification) and will include 200 nurse surveys and 20 interviews.

His team is bringing a biomedical informatics approach that could potentially help nurses and other care team members fine tune risk stratification to improve personalized care for higher risk patients and better predict what types of care they need.

“It’s this intersection of human-computer interaction, how they’re working with these computational tools within the electronic health record to improve patient outcomes,” said Williams, an assistant professor in the College of Medicine Department of Biomedical Informatics.

Williams’ prior research found that patient care teams with registered nurses saw reduced hospitalizations and readmissions for all congestive heart failure patients. The study was published in the journal PLOS One, and it is the foundation for his NIH/NINR-funded study.

The PLOS One paper reported that registered nurses were the only members of patients’ care teams consistently associated with a 30% decreased risk of hospitalization and a 31% decreased risk of readmissions for heart failure patients. The findings were based on analyses of 80,921 heart failure patient care encounters at UAMS from 2014 to 2021.

“This project is literally about the nurses and the hard work that they do to demonstrate that UAMS is a leader in both nursing and nursing science,” Williams said. “We know nurses are doing something right. Now they will help us generate evidence about what’s working at the bedside and help us create tools and interventions to optimize care here at UAMS and nationally.”  

Williams’ co-investigators on the grant are:

• Kevin Sexton, M.D., associate professor, College of Medicine Department of Surgery; president, BioVentures LLC at UAMS; co-director, TRI Health Science Innovation and Entrepreneurship program.
• Taren Swindle, Ph.D., associate professor, College of Medicine Department of Family and Preventive Medicine
• Pearman Parker, Ph.D., RN, assistant professor, College of Nursing

Williams’ work has been supported by the UAMS Translational Research Institute (TRI) through its KL2 Mentored Research Career Development Scholar Award program. He graduated from the program in 2023 after receiving two years of research funding and translational research training.

TRI is supported by the NIH National Center for Advancing Translational Sciences, Clinical and Translational Science Award number TR003107. 

All are invited to hear J. Rob Singleton, M.D., from the University of Utah, present, “Translational Science: Understand and Embrace the Discipline as a Part of Your Research Portfolio,” Tuesday, Feb. 13, 1 – 2 p.m., via Zoom.

This important TRI innOVATION Seminar will help you understand the difference between translational science and translational research, plus the benefits of incorporating translational science elements into your research activities. The CME presentation will include examples of translational science across the translational research spectrum.

Since 2010, Singleton has directed the Clinical Trial Services Foundation (CTSF) at the Utah Clinical and Translational Science Award (CTSA) site where he oversees the 70+ protocols currently using the CTSF. He is a professor and vice chair in the University of Utah Department of Neurology and site principal investigator for the NIH National Institute of Neurological Disorders and Stroke NeuroNEXT clinical trials consortium. 

Register here.

CME Information:

Speaker: Rob Singleton, M.D.

Topic: Translational Science: Understand and Embrace the Discipline as a Part of Your Research Portfolio

Objectives:  At the conclusion of this activity, the participant will be able to:

1. Understand the difference between Translational Research and Translational Science

2. Learn examples of Translational Science across the translational research spectrum

3. Understand the benefits of incorporating Translation Science elements into their research activities

Date/Time:    Tuesday February 13^th/1:00 PM                  

Location: Zoom Register here

Accreditation: In support of improving patient care, this activity has been planned and implemented by University of Arkansas for Medical Sciences. University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation:  The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation: The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1 ANCC contact hour(s).  Nurses must attend the entire session In order to receive credit.

ACPE Credit Designation: These knowledge based activities will provide pharmacists up to 1 contact hour(s) or .10 CEU.  Credit will be uploaded to CPE Monitor within 60 days of the session. JA0000298-0000-23-070-L01-P/T

Disclosure of Financial Relationships:

The planners of this RSS, Martha Rojo, RN and Corey Hayes have no relevant financial relationships with ineligible companies to disclose.

The following planners and moderators of this RSS have financial relationship(s) with ineligible companies to disclose:

Jessica Snowden, M.D., Pfizer, Consulting Fee

All relevant financial relationships have been mitigated.

The speaker of this RSS has no relevant financial relationships with ineligible companies to disclose.

The accreditation compliance reviewers of this RSS, Brandie Jones, Sara Hale, and Courtney Bryant, have no relevant financial relationships with ineligible companies to disclose.